Cardiovascular consequences of obesity and targets for treatment

Drug Discovery Today: Therapeutic Strategies

Volumn 5, Issue 1, 2008, Pages 53-61

  Mittendorfer, Bettina ^a   Peterson, Linda R ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CENTRAL NERVOUS SYSTEM AGENTS; DEXFENFLURAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENFLURAMINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; SIBUTRAMINE; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

ATHEROSCLEROTIC PLAQUE; BARIATRIC SURGERY; BLOOD VESSEL COMPLIANCE; BLOOD VESSEL REACTIVITY; BODY MASS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETOGENESIS; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG RESEARCH; DRUG TARGETING; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; EXERCISE; FATTY ACID OXIDATION; FUNCTIONAL ASSESSMENT; HEART ASSIST DEVICE; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPOSUCTION; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; THROMBOGENESIS; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; VALVULAR HEART DISEASE; VASCULAR ENDOTHELIUM; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

EID: 57249094367     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2008.07.001     Document Type: Review

References (78)

1. Rosamond W., et al. Heart diseases and stroke statistics - 2008 update. Circulation 117 (2008) e25-e146
2. Bogers R.P., et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch. Intern. Med. 167 (2007) 1720-1728
3. Kenchaiah S., et al. Obesity and the risk of heart failure. N. Engl. J. Med. 347 (2002) 305-313
4. Hu G., et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch. Intern. Med. 164 (2004) 1066-1076
5. Lakka H.M., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
6. Krauss R.M., et al. Obesity: impact of cardiovascular disease. Circulation 98 (1998) 1472-1476
7. Poirier P., et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 968-976
8. Cassis L.A., et al. Location and regulation of rat angiotensinogen messenger RNA. Hypertension 11 6 Pt 2 (1988) 591-596
9. Cassis L.A., et al. Characterization and regulation of angiotensin II receptors in rat adipose tissue. Angiotensin receptors in adipose tissue. Adv. Exp. Med. Biol. 396 (1996) 39-47
10. Alpert M.A. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am. J. Med. Sci. 321 (2001) 225-236
11. Davy K.P. The global epidemic of obesity: are we becoming more sympathetic?. Curr. Hypertens. Rep. 6 (2004) 241-246
12. Yudkin J.S., et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 972-978
13. Pauletto P., and Rattazzi M. Inflammation and hypertension: the search for a link. Nephrol. Dial Transplant. 21 (2006) 850-853
14. Klein S., et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 110 (2004) 2952-2967
15. Nordestgaard B.G., et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298 (2007) 299-308
16. Bansal S., et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298 (2007) 309-316
17. Lewis G.F. Fatty acid regulation of very low density lipoprotein production. Curr. Opin. Lipidol. 8 (1997) 146-153
18. Rader D.J. Molecular regulation of HDL metabolism and function: implications for novel therapies. J. Clin. Invest. 116 (2006) 3090-3100
19. Taskinen M.R. Lipoprotein lipase in diabetes. Diabetes Metab. Rev. 3 (1987) 551-570
20. Dattilo A.M., and Kris-Etherton P.M. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am. J. Clin. Nutr. 56 (1992) 320-328
21. Vitale C., et al. Gender-specific characteristics of atherosclerosis in menopausal women: risk factors, clinical course and strategies for prevention. Climacteric 10 Suppl. 2 (2007) 16-20
22. Ozcan U., et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306 (2004) 457-461
23. Zhou Y.T., et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc. Natl. Acad. Sci. U S A 97 (2000) 1784-1789
24. Listenberger L.L., et al. Palmitate-induced apoptosis can occur through a ceramide-independent pathway. J. Biol. Chem. 276 (2001) 14890-14895
25. Olson T.P., et al. Vascular structure and function in women: relationship with body mass index. Am. J. Prev. Med. 30 (2006) 487-492
26. Darvall K.A., et al. Obesity and thrombosis. Eur. J. Vasc. Endovasc. Surg. 33 (2007) 223-233
27. Pena A.S., et al. Vascular endothelial and smooth muscle function relates to body mass index and glucose in obese and nonobese children. J. Clin. Endocrinol. Metab. 91 (2006) 4467-4471
28. Eringa E.C., et al. Selective resistance to vasoactive effects of insulin in muscle resistance arteries of obese Zucker (fa/fa) rats. Am. J. Physiol. Endocrinol. Metab. 293 (2007) E1134-E1139
29. Makimattila S., et al. Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus. Circulation 94 (1996) 1276-1282
30. Vogel R.A., et al. Effect of a single high-fat meal on endothelial function in healthy subjects. Am. J. Cardiol. 79 (1997) 350-354
31. Guzik T.J., et al. Adipocytokines - novel link between inflammation and vascular function?. J. Physiol. Pharmacol. 57 (2006) 505-528
32. Brook R.D. Obesity, weight loss, and vascular function. Endocrine 29 (2006) 21-25
33. Fruhbeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes 48 (1999) 903-908
34. Momin A.U., et al. Leptin is an endothelial-independent vasodilator in humans with coronary artery disease: evidence for tissue specificity of leptin resistance. Eur. Heart J. 27 (2006) 2294-2299
35. Bisoendial R.J., et al. Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects. J. Lipid Res. 48 (2007) 952-960
36. Chudek J., and Wiecek A. Adipose tissue, inflammation and endothelial dysfunction. Pharmacol. Rep. 58 Suppl. (2006) 81-88
37. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
38. Esper R.J., et al. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc. Diabetol. 5 (2006) 4
39. Rott D., et al. IL-6 is produced by splenocytes derived from CMV-infected mice in response to CMV antigens, and induces MCP-1 production by endothelial cells: a new mechanistic paradigm for infection-induced atherogenesis. Atherosclerosis 170 (2003) 223-228
40. Scheiffer B., et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation 110 (2004) 3493-3500
41. Hamanaka R., et al. Induction of low density lipoprotein receptor and a transcription factor SP-1 by tumor necrosis factor in human microvascular endothelial cells. J. Biol. Chem. 267 (1992) 13160-13165
42. Rajavashisth T.B., et al. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J. Biol. Chem. 274 (1999) 11924-11929
43. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 189 (2006) 47-60
44. Towler D.A. Imaging aortic matrix metabolism: mirabile visu!. Circulation 115 (2007) 297-299
45. Abdollahi M., et al. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb. Haemost. 89 (2003) 493-498
46. Dandona P., et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111 (2005) 1448-1454
47. Mensah G.A., et al. Patterns of body fat deposition in youth and their relation to left ventricular markers of adverse cardiovascular prognosis. Am. J. Cardiol. 84 (1999) 583-588
48. Peterson L.R., et al. Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. J. Am. Coll. Cardiol. 43 (2004) 1399-1404
49. Wong C.Y., et al. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation 110 (2004) 3081-3087
50. Gates P.E., et al. Adiposity contributes to differences in left ventricular structure and diastolic function with age in healthy men. J. Clin. Endocrinol. Metab. 88 (2003) 4884-4890
51. Stoddard M.F., et al. The influence of obesity on left ventricular filling and systolic function. Am. Heart J. 124 (1992) 694-699
52. Berkalp B., et al. Obesity and left ventricular diastolic dysfunction. Int. J. Cardiol. 52 (1995) 23-26
53. Carabello B.A., and Gittens L. Cardiac mechanics and function in obese normotensive persons with normal coronary arteries. Am. J. Cardiol. 59 (1987) 469-473
54. Palmieri V., et al. Relation of various degrees of body mass index in patients with systemic hypertension to left ventricular mass, cardiac output, and peripheral resistance (The Hypertension Genetic Epidemiology Network Study). Am. J. Cardiol. 88 (2001) 1163-1168
55. Chiu H.C., et al. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ. Res. 96 (2005) 225-233
56. Aasum E., et al. Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes 52 (2003) 434-441
57. Chiu H.C., et al. A novel mouse model of lipotoxic cardiomyopathy. J. Clin. Invest. 107 (2001) 813-822
58. Peterson L.R., et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 109 (2004) 2191-2196
59. Szczepaniak L.S., et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn. Reson. Med. 49 (2003) 417-423
60. Sharma S., et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 18 (2004) 1692-1700
61. Leichman J.G., et al. Association of plasma free fatty acids and left ventricular diastolic function in patients with clinically severe obesity. Am. J. Clin. Nutr. 84 (2006) 336-341
62. Vincent H.K., et al. Obesity is associated with increased myocardial oxidative stress. Int. J. Obes. Relat. Metab. Disord 23 (1999) 67-74
63. Radovits T., et al. The peroxynitrite decomposition catalyst FP15 improves ageing-associated cardiac and vascular dysfunction. Mech. Ageing Dev. 128 (2007) 173-181
64. 2). Am. J. Cardiol. 98 (2006) 1593-1598
65. Alpert M.A., et al. Effect of weight loss on cardiac chamber size, wall thickness and left ventricular function in morbid obesity. Am. J. Cardiol. 55 (1985) 783-786
66. Boudina S., et al. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 56 (2007) 2457-2466
67. Foster G.D., et al. A randomized trial of a low-carbohydrate diet for obesity. N. Engl. J. Med. 348 (2003) 2082-2090
68. Tejada T., et al. Nonpharmacologic therapy for hypertension: does it really work?. Curr. Cardiol. Rep. 8 (2006) 418-424
69. Israili Z.H., et al. Metabolic syndrome: treatment of hypertensive patients. Am. J. Ther. 14 (2007) 386-402
70. Sjostrom L., et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351 (2004) 2683-2693
71. Klein S., et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N. Engl. J. Med. 350 (2004) 2549-2557
72. Adams T.D., et al. Long-term mortality after gastric bypass surgery. N. Engl. J. Med. 357 (2007) 753-761
73. Sjostrom L., et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N. Engl. J. Med. 357 (2007) 741-752
74. Wirth A., and Kroger H. Improvement of left ventricular morphology and function in obese subjects following a diet and exercise program. Int. J. Obes. Relat. Metab. Disord. 19 (1995) 61-66
75. Jordan J., et al. Reduction of weight and left ventricular mass with serotonin uptake inhibition in obese patients with systemic hypertension. Am. J. Cardiol. 75 (1995) 743-744
76. Himeno E., et al. A weight reduction and weight maintenance program with long-lasting improvement in left ventricular mass and blood pressure. Am. J. Hypertens. 12 (1999) 682-690
77. Peterson L.R., et al. Moderate weight loss decreases myocardial oxygen consumption and cardiac work in obese men and women. J. Am. Coll. Cardiol. 47 (2006) 105A
78. Ley R.E., et al. Microbial ecology: human gut microbes associated with obesity. Nature 444 (2006) 1022-1023